Keywords: Myrexism Devekopment strategy, Azixa, Myriadm Fourth-quarter 2011 results, CEO, Oncology, Auto-immune diseases
Myrexis to drop development of Azixa; 4th-qtr loss widens; names new CEO
Article | 13 September 2011
US biotech firm Myrexis (Nasdaq: MYRX), previously known as Myriad Pharmaceuticals, saw its shares fall 4.6% to $2.70 in after-hours trading last ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- SciClone gains China rights to Zensun's Neucardin
